Sponsored by:
Pathology and Laboratory Medicine
Grand Rounds
Academic Year 2013-2014
“Targeted Therapy of Cancer: From Oncogenes to Dream Teams”
Monday, September 30, 2013
12:00PM-1:00PM
CRB, Austrian Auditorium
Jeff Drebin, MD, PhD, FACS
University of Pennsylvania, Penn Medicine
Department of Surgery
Target Audience
This program has been designed for departmental/institutional faculty, fellows and residents in the medical specialties
of anatomic pathology, neuropathology, laboratory medicine, and transfusion medicine.
Educational Objectives
After completing this activity, participants should be able to:
 Discuss current thinking about topics in pathology and laboratory medicine
 Recognize biomedical research as it relates to the pathologic basis of disease
 Distinguish timely topics in modern science and medicine
 Recognize the early evolution of targeted therapies of breast cancer and the accelerating timeline of drug
development for targeted therapies in general.
 Identify the role of beta-catenin transcription in linking NF-kB signaling to colon cancer and the potential
importance for targeted therapy and chemoprevention.
 Discuss how advances in DNA sequencing, analysis of tumor metabolism, and studies of tumor-stromal
interactions may lead to novel approaches to pancreas cancer.
Accreditation
The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 1 AMA
PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in
the activity.
Acknowledgement of Commercial Support*
NONE
For more information, please contact
Marla Knob
215-746-5772
Marla2@mail.med.upenn.edu
Check your CME online at www.penncmeonline.com
Disclosure of Relevant Financial Relationships and Unapproved Uses of Products
It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to
control the content of an educational activity to disclose to the learners all relevant financial relationships that they have
with any commercial interest that provides products or services that may be relevant to the content of this continuing
medical education activity. For this purpose we consider relationships of the person involved in the CME activity to
include financial relationships of a spouse or partner.
The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from
involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in
improving medical practice, are based on valid content, and are independent of control from commercial interests and
free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure
information provided to the Penn Office of CME was found to contain relationships that created a conflict of interest
relative to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically
rigorous and evidence-based presentations.
The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania, Mila Kostic,
Director of CME and the peer reviewer Zalman Agus, MD, Associate Dean for CME, have disclosed that they have
no relevant financial relationships with any commercial interests related to the content of this educational activity.
The following individuals have disclosed that they have no relevant financial relationships with any commercial interests
related to the content of this educational activity:
PLANNING COMMITTEE MEMBER NAME
TAKU KAMBAYASHI,MD, PHD
KATHLEEN MONTONE, MD
PRESENTER NAME
The following individuals have reported the listed relevant financial relationships with commercial interests related to
the content of this educational activity.
PLANNING COMMITTEE MEMBER NAME
NAME OF COMMERCIAL INTEREST
RELATIONSHIP
WARREN S. PEAR, MD, PHD
AMGEN & PFIZER
STOCK
IDEON HEALTH CARE
SPOUSE HONORARIUM
PRESENTER NAME
NAME OF COMMERCIAL INTEREST
RELATIONSHIP
Jeff Drebin, MD, PhD, FACS
Roche/Genetech
Inventor
Glaxo, Smith, Kline
Scientist
Relevant Financial Relationships: Financial relationships are those relationships in which the individual benefits by receiving a salary,
royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership
interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as
employment, management position, independent contractor (including contracted research), consulting, speaking and teaching,
membership on advisory committees or review panels, board membership, and other activities from which remuneration is received
or expected
DISCLOSURE OF UNAPPROVED USES OF PRODUCTS
PRESENTER NAME
PRODUCT
INVESTIGATIONAL AND/OR OFF-LABEL USE